PharmaVOICE - 
March 2002
Purchase Issue

In Every Issue
Talent Pool
Pharma POOL Damian BRAGA Wayne PISANO David J. WILLIAMS Aventis [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Newton Interactive [...]
By
What’s New
Ribotsky Worldwide Inc., a fullservice communications company, has expanded its [...]
By
PharmaTrax
Internet’s IMPACT ON MEDICAL DECISIONS IS GROWING The Internet is [...]
By
For Art’s Sake
CREATIVE review What’s black and white and read all over? [...]
By
PharmaOutlet
In a nod to the founding fathers, several states have [...]
By

Don Sharpe

What’s on your mind: Opinions
The Time Has Come The idea of setting up a [...]
By
Raise Your Voice: Letters
Wow! Great! Fantastic! Finally! Over the years I have been [...]
By
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh [...]
By

Taren Grom, Editor

On The Cover

The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Challenge CREATIVE The Creativity in [...]
By

Taren Grom, Editor

Features

Mark Eisenach — The Mark of a Leader
With more than 75% of all clinical trials failing to meet enrollment deadlines, costing drug makers more than a million dollars a day in potential sales, Mark Eisenach’s mission is to  help solve the  industry’s chronic problem surrounding patient and  investigator recruitment. Mark LEADER of a THE 65 MARK Eisenach first as a consultant with The Boston Consulting Group, then as a top [...]
By

Kim Ribbink

Vanlev: Coming Soon
In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was set to seek approval for Vanlev, but [...]
By

Deborah Ruriani

Moving Beyond The Click
Based on both public and proprietary research, it is clear that the Internet is proving to be an effective tool for engaging actual and potential prescribers for a given brand or class of drugs in an intellectual dialog that can change prescribing behavior dramatically. FRED FOARD HAS WATCHED THE EVOLUTION OF THE I NTERNET W [...]
By
The Industry’s Top Guns Are Revolving
The year started with surprising news. In January, Gil Bashe joined Catalyst Communications Inc. as president and CEO. Mr. Bashe, 47, had served as CEO of Health!Quest Global Communication Partners, a private equitysponsored communications network, which was funded by GTCR Golder Rauner LLC, since January 2000. The role of CEO at Catalyst is new. At [...]
By
Pricing — The Cost of Doing Business
PICK UP A NEWSPAPER , TURN ON THE TELEVISION, OR LOG ONTO THE INTERNET and almost every week, a politician, agency, or consumer group can be found criticizing the pharmaceutical industry’s pricing, promotional, or marketing practices. Central to the controversy, more often than not, is the cost of phar maceutical products and the impact this [...]
By

Denise Myshko

Outsourcing: Division of Labor
DIVISION OF LABOR There are about 7,500 projects under development by pharmaceutical and biotechnology companies worldwide, and an estimated 80,000 clinical trials are conducted globally every year. Today, 80% of these clinical trials are funded by private industry rather than by government, according to published reports. With so many potential drugs under review, there is [...]
By
FEEDBACK